CA
NZ
UK
AU
IND
US
Post-transplant lymphoproliferative disease driven by the Epstein-Barr virus is a rare and frequently fatal complication in immunocompromised transplant recipients. StandardOptionsincluding rituximab and chemotherapy carry limited efficacy in relapsed or refractory cases, and the clinical community has long recognized the need for a targeted cellular …
Bladder cancer is one of the most common malignancies in the developed world, and the subset defined as high-risk, BCG-unresponsive non-muscle invasive bladder cancer represents a particularly difficult clinical problem. Bacillus Calmette-Guérin immunotherapy has long served as the backbone of treatment for NMIBC, yet …
Ovarian cancer remains one of the most lethal gynecologic malignancies, largely because the majority of patients are diagnosed at an advanced stage when surgical and chemotherapeuticOptionsoffer limited long-term benefit. The field has increasingly turned toward immunotherapy, particularly checkpoint inhibitors, to address the unmet need …
In the diagnostics industry, clinicalUtilityalone does not generate revenue. A laboratory test or assay platform becomes commercially viable only when it can be billed to payers, and Medicare enrollment is the essential first step in that process. For Plus Therapeutics' CNSide Diagnostics subsidiary, the …
Duchenne muscular dystrophy is among the most serious and well-characterized rare genetic diseases affecting children globally. Caused by mutations in the dystrophin gene, DMD leads to progressive muscle degeneration, loss of independent ambulation, and eventual cardiorespiratory failure. The condition disproportionately affects young males, and …
Apyx Medical occupies a distinctive position in the medical technology landscape as the developer of Renuvion, a helium plasma-based energy delivery platform cleared by the FDA for use in multiple aesthetic and surgical body contouring applications. Unlike the clinical-stage companies in this sector, Apyx …
When Coinbase Global steps up to report its first-quarter 2026Earningsafter Thursday's closing bell, it will do so under conditions that few at the company would have chosen. A prolonged slump inCryptocurrency Trading, a workforce reduction that rattled employees earlier this week, a damning preview …
Beating Estimates in a Quarter Nobody Expected to Be Easy
An Earnings Beat Built on Disruption
Insulet Corporation (Nasdaq:PODD) beat Q1 2026Earningsexpectations with 34%Revenuegrowth and a 40% EPS surge, yet shares fell nearly 10%. Here is what the numbers reveal.Key HighlightsQ1 2026 revenue rose 34% year-over-year to USD 761.7 million, exceeding the analyst consensus of USD 728.36 million.Adjusted EPS of …
Please wait processing your request...